Thus, combinatorial treatment with selective JAK2 inhibitors and CD19 CAR-T cells represents an attractive therapeutic option for JAK2 mutant Ph-like ALL, which is an aggressive B-ALL subtype resistant to standard chemotherapies that often acquires JAK2 mutations. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.